However, existing studies on EZH2 degradation in cancer cells have predominantly centered on the ubiquitin‐proteasome system.[20] Further investigation is warranted to determine whether alternative degradation mechanisms for EZH2 are involved, particularly in the context of OSCC. Here, EZH2 is linked to cancer.